Clinical Trial Supported by $2.1M ADDF Grant to Test Cancer Treatment in Alzheimer’s Patients

Clinical Trial Supported by $2.1M ADDF Grant to Test Cancer Treatment in Alzheimer’s Patients
The Alzheimer’s Drug Discovery Foundation (ADDF) announced that a Georgetown University Medical Center researcher has been awarded a $2.1 million grant to conduct a Phase 2 clinical trial of low-dose nilotinib (Tasigna, a cancer therapy) in patients with Alzheimer’s disease. The grant was awarded as part of the ADDF’s initiative “Learning from Cancer Advance Treatments for

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *